Copyright
©The Author(s) 2016.
World J Radiol. Oct 28, 2016; 8(10): 829-845
Published online Oct 28, 2016. doi: 10.4329/wjr.v8.i10.829
Published online Oct 28, 2016. doi: 10.4329/wjr.v8.i10.829
Ref. | Year of pub | Tracer | Sensitivity | Specificity |
Meisner et al[6] | 2007 | 18F-FDG | ||
UC | 95.8% | NA | ||
CD | 81.3% | NA | ||
Das et al[1] | 2010 | 18F-FDG | 98.5% | NA |
Ahmadi et al[7] | 2010 | 18F-FDG | NA | NA |
Groshar et al[20] | 2010 | 18F-FDG | NA | NA |
Shyn et al[21] | 2010 | 18F-FDG | ||
Detection of bowel segments with active CD | ||||
Using a threshold > 1 (at least mild activity) | 63.3% | 100% | ||
Using a threshold > 2 (at least moderate activity) | 100% | 89.7% | ||
Holtmann et al[2] | 2012 | 18F-FDG | ||
Detection of active CD | ||||
In the terminal ileum + colon (on a per segment-based analysis) | 90% | 92.6% | ||
In the proximal ileum (on a per patient-based analysis) | 100% | 100% | ||
Lenze et al[4] | 2012 | 18F-FDG | ||
Detection of CD strictures | 81% | NA | ||
Differentiation of the nature of | ||||
All strictures | 53% | |||
Only inflammatory ones | 83% | |||
Only fibromatous ones | 11% | |||
Only mixed ones | 0% | |||
Treglia et al[65] (meta-analysis) (on a per segment-based analysis) | 2013 | 18F-FDG | 85% | 87% |
Zhang et al[3] (meta-analysis) 18F-FDG On per-bowel-segment basis On per-patient basis | 2014 | 18F-FDG, 99mTc-HMPAO, 99mTc-monoclonal antigranulocyteantibody | 0.84 0.59 | 0.86 1 |
99mTc-HMPAO | 0.86 | 0.50 | ||
On per-bowel-segment basis | 0.79 | 0.76 | ||
On per-patient basis | 0.91 | 0.85 | ||
99mTc-monoclonal antigranulocyte antibody on per-bowel-segment basis | 0.45 | 0.94 | ||
Catalano et al[5] | 2016 | 18F-FDG | (Mean) | (Mean) |
Detection of fibrotic CD strictures by | ||||
ADC × SUVmax < 3000 | 0.67 | 0.73 | ||
SI on T2-weightedimages × SUVmax < 2000 | 0.77 | 0.57 | ||
SUVmax < 2.5 | 0.79 | 0.61 | ||
ADC < 1250 × 10-3 mm2/s | 0.84 | 0.26 | ||
SI on T2-weightedimages < 750 | 0.73 | 0.13 |
- Citation: Caobelli F, Evangelista L, Quartuccio N, Familiari D, Altini C, Castello A, Cucinotta M, Di Dato R, Ferrari C, Kokomani A, Laghai I, Laudicella R, Migliari S, Orsini F, Pignata SA, Popescu C, Puta E, Ricci M, Seghezzi S, Sindoni A, Sollini M, Sturiale L, Svyridenka A, Vergura V, Alongi P, Young AIMN Working Group. Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art. World J Radiol 2016; 8(10): 829-845
- URL: https://www.wjgnet.com/1949-8470/full/v8/i10/829.htm
- DOI: https://dx.doi.org/10.4329/wjr.v8.i10.829